[go: up one dir, main page]

BRPI0517473A - tratamento de mastite - Google Patents

tratamento de mastite

Info

Publication number
BRPI0517473A
BRPI0517473A BRPI0517473-2A BRPI0517473A BRPI0517473A BR PI0517473 A BRPI0517473 A BR PI0517473A BR PI0517473 A BRPI0517473 A BR PI0517473A BR PI0517473 A BRPI0517473 A BR PI0517473A
Authority
BR
Brazil
Prior art keywords
mastitis treatment
treatment
mastitis
mastite
enrofloxacin
Prior art date
Application number
BRPI0517473-2A
Other languages
English (en)
Inventor
Franz Pirro
Kristine Fraatz
Robrecht Froyman
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35462240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0517473(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of BRPI0517473A publication Critical patent/BRPI0517473A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

TRATAMENTO DE MASTITE. A presente invenção refere-se ao tratamento simplificado da mastite com enrofloxacina ou ciprofloxacina, particularmente em vacas.
BRPI0517473-2A 2004-11-12 2005-10-28 tratamento de mastite BRPI0517473A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004054873A DE102004054873A1 (de) 2004-11-12 2004-11-12 Behandlung von Mastitis
PCT/EP2005/011553 WO2006050826A2 (de) 2004-11-12 2005-10-28 Behandlung von mastitis mit enrofloxacin

Publications (1)

Publication Number Publication Date
BRPI0517473A true BRPI0517473A (pt) 2008-10-07

Family

ID=35462240

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517473-2A BRPI0517473A (pt) 2004-11-12 2005-10-28 tratamento de mastite

Country Status (27)

Country Link
US (2) US20070265275A1 (pt)
EP (1) EP1812002B1 (pt)
JP (2) JP2008519781A (pt)
KR (1) KR20070084182A (pt)
CN (1) CN101056638A (pt)
AR (1) AR051763A1 (pt)
AT (1) ATE526970T1 (pt)
BR (1) BRPI0517473A (pt)
CA (1) CA2587187A1 (pt)
CR (1) CR9109A (pt)
DE (2) DE102004054873A1 (pt)
DK (1) DK1812002T3 (pt)
ES (1) ES2373449T3 (pt)
HR (1) HRP20120002T1 (pt)
IL (1) IL182993A (pt)
MX (1) MX2007005526A (pt)
NO (1) NO20072890L (pt)
NZ (1) NZ555062A (pt)
PE (1) PE20061139A1 (pt)
PL (1) PL1812002T3 (pt)
PT (1) PT1812002E (pt)
RU (1) RU2413514C2 (pt)
SI (1) SI1812002T1 (pt)
SV (1) SV2006002296A (pt)
UA (1) UA92593C2 (pt)
WO (1) WO2006050826A2 (pt)
ZA (1) ZA200703695B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5217276B2 (ja) * 2007-07-19 2013-06-19 ニプロ株式会社 注射用抗菌剤の製造方法
GB2480276A (en) * 2010-05-11 2011-11-16 Michael Hilary Burke Process for the preparation of an aqueous injectable enrofloxacin antimicrobial formulation
CN101933927A (zh) * 2010-06-30 2011-01-05 洛阳惠中兽药有限公司 一种含恩诺沙星六水合物组合物及其在制备治疗或预防家畜疾病的药物中的应用
US10265330B2 (en) * 2012-06-29 2019-04-23 Bayer Animal Health Gmbh Pharmaceutical compositions and treatment of mastitis
EP2968231B1 (en) * 2013-03-15 2020-07-01 Boehringer Ingelheim Animal Health USA Inc. Antimicrobial polyamide compositions and mastitis treatment
RU2655772C1 (ru) * 2016-12-26 2018-05-29 Федеральное государственное бюджетное научное учреждение "Курский научно-исследовательский институт агропромышленного производства" Йодсодержащий состав для лечения мастита у коров
RU2652354C1 (ru) * 2017-11-07 2018-04-25 федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный аграрный университет" (ФГБОУ ВО Волгоградский ГАУ) Способ терапии коров, больных маститом
CN108051512A (zh) * 2017-11-27 2018-05-18 佛山科学技术学院 一种牛乳中氟喹诺酮类药物残留量的检测方法
CN110812326B (zh) * 2019-11-04 2022-04-22 黑龙江省农业科学院畜牧兽医分院 一种辛伐他汀混悬乳剂及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
DE3333719A1 (de) 1983-09-17 1985-04-04 Bayer Ag Loesungen milchsaurer salze von piperazinylchinolon- und piperazinyl-azachinoloncarbonsaeuren
DE3517709A1 (de) 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
DE3537761A1 (de) 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
DE3713672A1 (de) * 1987-04-24 1988-11-17 Bayer Ag Verfahren zur herstellung von parenteral verabreichbaren chinoloncarbonsaeuren
DE19500784A1 (de) 1995-01-13 1996-07-18 Bayer Ag Enrofloxacin-Injektions- oder Infusionslösungen
CA2176298C (en) 1995-06-27 2009-01-27 Dennis D. Copeland A single high dose fluoroquinolone treatment
GB0229642D0 (en) * 2002-12-20 2003-01-22 Pfizer Ltd Veterinary compositions for treating mastitis

Also Published As

Publication number Publication date
PL1812002T3 (pl) 2012-03-30
WO2006050826A2 (de) 2006-05-18
CA2587187A1 (en) 2006-05-18
US20070265275A1 (en) 2007-11-15
DK1812002T3 (da) 2012-02-06
US20130023540A1 (en) 2013-01-24
CN101056638A (zh) 2007-10-17
RU2007121516A (ru) 2008-12-20
ES2373449T3 (es) 2012-02-03
JP2013063985A (ja) 2013-04-11
WO2006050826A3 (de) 2006-07-27
DE202005022066U1 (de) 2012-12-06
PE20061139A1 (es) 2006-12-29
HRP20120002T1 (hr) 2012-02-29
MX2007005526A (es) 2007-07-09
SI1812002T1 (sl) 2012-03-30
NZ555062A (en) 2009-12-24
DE102004054873A1 (de) 2006-05-18
RU2413514C2 (ru) 2011-03-10
EP1812002B1 (de) 2011-10-05
SV2006002296A (es) 2006-06-26
NO20072890L (no) 2007-06-06
KR20070084182A (ko) 2007-08-24
IL182993A0 (en) 2007-09-20
JP2008519781A (ja) 2008-06-12
EP1812002A2 (de) 2007-08-01
UA92593C2 (ru) 2010-11-25
ATE526970T1 (de) 2011-10-15
AR051763A1 (es) 2007-02-07
CR9109A (es) 2007-10-04
ZA200703695B (en) 2008-08-27
IL182993A (en) 2013-03-24
PT1812002E (pt) 2011-12-30

Similar Documents

Publication Publication Date Title
BRPI0920041A2 (pt) composições e processos relacionados às proteínas eap, emp e/ou adsa bacterianas
BRPI0718146A2 (pt) Dispositivos de infusão e métodos
EA200701918A1 (ru) Белок липокалин
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
CR9109A (es) Tratamiento de mastitis
BRPI0807760A2 (pt) Bactérias corineformes com atividade de formato-thf-sintetase e/ou atividade de clivagem de glicina
ATE424159T1 (de) Katheter
NO20083245L (no) Sykliske antimikrobielle peptider
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
BRPI0908096A2 (pt) Derivado de 2-aza-biciclo [2.2.1] heptano
WO2010132839A3 (en) Aminoglycoside dosing regimens
WO2007118130A3 (en) Antibacterial agents
BRPI0722054A2 (pt) Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico.
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
MX2009012767A (es) Metodos de tratamiento de infecciones fungicas.
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
UA91848C2 (ru) Применение соединений диосметина в лечении и предотвращении тромботическим патологиям
WO2006081289A3 (en) Antibacterial agents
WO2008105826A3 (en) Compositions compromising lysostaphin variants and methods of using the same
SG170804A1 (en) Pseudomonas aeruginosa outer membrane protein pa0427
WO2006081182A3 (en) Antibacterial agents
DE602005015963D1 (de) Estergebundene makrolide, die sich für die behandlung von mikrobiellen infektionen eignen
WO2006081178A3 (en) Antibacterial agents
NO20091386L (no) Fenyloksyanilinderivater
DE502005008925D1 (de) Substituierte nonadepsipeptide

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAYER ANIMAL HEALTH GMBH (DE)

Free format text: TRANSFERIDO DE: BAYER HEALTHCARE AG

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.